Scancell completes up to US$25m in debt financing

Summary by AI BETAClose X

Scancell Holdings plc has secured up to US$25 million in debt financing from funds managed by BlackRock, which will be available in four tranches and is intended to fund the Phase 3 development of iSCIB1+ alongside equity investment. The first US$7 million drawdown is conditional on shareholder approval, with further tranches totaling US$8 million expected upon completion of US Listing Transactions and the opening of the first clinical site for the Phase 3 study. Interest rates are 10.50% per annum for cash payments and 10.95% per annum for capitalised interest on convertible tranches, with the lender having the option to convert up to US$5 million into ordinary shares at a 30% premium. The company will also grant warrants representing 4.5% of each drawdown amount.

Disclaimer*

UK 100

Latest directors dealings